B
Bullisch
Bullisch · 25%IART
$15.78
Szenariopreis
$12.325
+0.505 (+4.10%)Zum Schluss
Loading chart…
- Hoch
- 12.360
- Eröffnung
- 11.690
- Volumengewichteter Durchschnittskurs
- 12.12
- Volumen
- 1.39M
- Marktkap.
- 2.27B
- Tief
- 11.660
- Umsatz
- 16.80M
- EV/EBITDA, TTM
- 3.87
Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
KI-Analyse of Integra Lifesciences Holdings Corp (IART)
HaltenIntegra Lifesciences Holdings Corp (IART) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $13.21, which is below the adjusted analyst price target of $15. Additionally, the RSI is at 36.99, indicating that the stock is nearing oversold territory but has not yet shown a strong reversal signal. The company has faced challenges, including a significant net income loss of $484 million in Q2 2025, which raises concerns about its profitability moving forward. However, the gross margin remains relatively healthy at 54.90% in Q2 2026, suggesting some operational efficiency. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth opportunities.
Analystenbewertungen (15)
+0.04% Aufwärtspotenzial
Kaufen
9 Kaufen
6 Halten
0 Verkaufen
Aktuell: 12.33
Tief
10.00
Durchschnitt
12.33
Hoch
14.00
BMO Capital
Market Perform
$15
2026-10-05
BMO Capital
2026-10-05
Kursziel
$15
Market Perform
Citi
Neutral
$15
2026-10-05
Citi
2026-10-05
Kursziel
$15
Neutral
Wells Fargo
Equal Weight
$15
2026-10-03
Wells Fargo
2026-10-03
Kursziel
$15
Equal Weight
UBS
Neutral
$19
2026-07-28
UBS
2026-07-28
Kursziel
$19
Neutral
Truist
Halten
$19
2026-07-16
Truist
2026-07-16
Kursziel
$19
Halten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Integra Lifesciences Holdings Corp (IART) beträgt 6.00, verglichen mit dem 5-Jahres-Durchschnitt von 11.62.
Alphio-AI-Kursszenarien für IART
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die IART halten
Event-Zeitleiste
News
9.510-21FoolIntegra Lowers 2026 Revenue Guidance Amid Flooding Impact
9.510-21NewsfilterIntegra LifeSciences Reports Q3 2026 Financial Results with Mixed Performance
- 1.010-16Newsfilter
Integra LifeSciences to Showcase ENT Innovations at AAO-HNSF Annual Meeting
- 8.510-09Newsfilter
Integra LifeSciences Prices $450 Million Senior Secured Notes Offering
4.510-05PRnewswireWall Street Market Dynamics Analysis
IART FAQ – beantwortet von Alphio AI
Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Integra Lifesciences Holdings Corp (IART) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $13.21, which is below the adjusted analyst price target of $15. Additionally, the RSI is at 36.99, indicating that the stock is nearing oversold territory but has not yet shown a strong reversal signal. The company has faced challenges, including a significant net income loss of $484 million in Q2 2025, which raises concerns about its profitability moving forward. However, the gross margin remains relatively healthy at 54.90% in Q2 2026, suggesting some operational efficiency. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth opportunities.
15 analysts cover IART: 9 rate it Buy, 6 Hold and 0 Sell. The average price target is 12.33.
Community
Mehr ↗
$IART Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.59, up 9.26% YoY • Reported revenue of $411.18M, up 2.27% YoY • Integra LifeSciences expects Q4 2026 revenue of $413M to $433M and adjusted diluted EPS of $0.61 to $0.71; FY2026 revenue of $1.63B to $1.65B and adjusted EPS of $2.30 to $2.40.
Mehr anzeigenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.